Antihemophilic factor concentrate therapy in von Willebrand disease. Dissociation of bleeding-time factor and ristocetin-cofactor activities.
Treatment of von Willebrand disease with two plasma antihemophilic factor (AHF) concentrates, cryoprecipitate and glycine-precipitated AHF, was compared. Both concentrates were equally effective in immediately raising the plasma levels of factor VIII, the factor VIII-related antigen, and the ristocetin-related von Willebrand factor (vWF) and in stimulating a secondary rise in plasma factor VIII. Given either concentrate, the vWF activity, the antigen, and factor VIII levels were normalized in a patient with von Willebrand disease. However, correction of the prolonged bleeding time and control of bleeding occurred only with the cryoprecipitate. The bleeding-time corrective factor and the ristocetin-related vWF or platelet-aggregating factor are dissociable, distinct activites.
D000941:Antigens; D001778:Blood Coagulation Disorders; D001780:Blood Coagulation Tests; D011232:Chemical Precipitation; D005169:Factor VIII / Q000627:therapeutic use*; D005998:Glycine; D006487:Hemostasis; D006801:Humans; D008297:Male; D008875:Middle Aged; D012310:Ristocetin / Q000097:blood*; D014842:von Willebrand Diseases / Q000188:drug therapy*
D000941:Antigens; D012310:Ristocetin; D005169:Factor VIII; D005998:Glycine